联拓生物签署协议转让其在中国及其他亚洲市场对NBTXR3的权利

January 22, 2024

https://www.globenewswire.com/news-release/2023/12/26/2801028/0/zh-hans/%E8%81%94%E6%8B%93%E7%94%9F%E7%89%A9%E7%AD%BE%E7%BD%B2%E5%8D%8F%E8%AE%AE%E8%BD%AC%E8%AE%A9%E5%85%B6%E5%9C%A8%E4%B8%AD%E5%9B%BD%E5%8F%8A%E5%85%B6%E4%BB%96%E4%BA%9A%E6%B4%B2%E5%B8%82%E5%9C%BA%E5%AF%B9NBTXR3%E7%9A%84%E6%9D%83%E5%88%A9.html

上海和新泽西州普林斯顿, Dec. 26, 2023 (GLOBE NEWSWIRE) — 联拓生物（纳斯达克代码：LIAN），一家致力于为中国和其他主要亚洲市场的患者提供创新药物的生物技术公司，于今日宣布其与强生旗下杨森（Janssen）制药公司就一款在研发阶段的潜在同类首创放疗增敏剂NBTXR3达成协议，将其在中国、韩国、新加坡和泰国的独家开发和商业化权利转让给杨森。

Read more at globenewswire.com

Related news for (LIAN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.